We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis

By LabMedica International staff writers
Posted on 05 Sep 2025

Autoimmune vasculitis and related conditions are difficult to diagnose quickly and accurately, often requiring multiple tests to confirm the presence of specific autoantibodies. More...

Traditional methods can be time-consuming, causing delays in initiating treatment and increasing patient anxiety. Now, a new multiplex assay can simultaneously detect multiple markers, offering faster, more comprehensive diagnostic insights for autoimmune vasculitis.

AliveDx’s (Vaud, Switzerland) MosaiQ AiPlex Vasculitis (VAS) assay is designed to detect three key autoantibody markers—MPO, PR3, and GBM—from just 10 µl of patient serum. The assay is intended to be used on the MosaiQ instrument, which recently received its own FDA Class II 510(k) exempt approval. The multiplex assay provides a single report covering all markers, streamlining workflows while aligning with international diagnostic guidelines.

AliveDx has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its MosaiQ AiPlex Vasculitis (VAS) assay, building on its earlier rollout in CE-marked regions, where it has already been in clinical use since July 2025. The system has demonstrated the ability to deliver comprehensive results that cover all three markers cited in the 2022 ACR/EULAR Classification Criteria for ANCA-associated vasculitides and the 2021 KDIGO Clinical Practice Guideline for glomerular diseases.

AliveDx has launched over 90 IVD products globally in the past year, adding assays for autoimmune diseases like celiac disease and connective tissue disorders. The MosaiQ AiPlex VAS assay adds to this growing menu, offering clinicians greater efficiency and faster results in diagnosing complex conditions. With FDA review underway, the company plans to expand the MosaiQ portfolio in the U.S., further supporting clinicians with comprehensive autoimmune diagnostic solutions.

“Submitting the 510(k) premarket notification to the FDA for our MosaiQ AiPlex VAS microarray is an important step in advancing innovative diagnostic solutions for clinicians and patients in the U.S,” said Manuel O. Méndez, CEO of AliveDx. “Globally, AliveDx and our partners are advancing our goal to deliver solutions that provide greater clinical and economic value, ultimately aiming to improve patient outcomes.”

Related Links:
AliveDx


New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Collection and Transport System
PurSafe Plus®
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LungCanSeek demonstrated an overall sensitivity of 83.5% and specificity of 90.3% in detecting lung cancer (Photo courtesy of AdobeStock)

New Blood Test Offers Affordable and Accurate Early Detection of Lung Cancer

Lung cancer remains the leading cause of cancer-related deaths worldwide, largely because most cases are diagnosed at advanced stages when treatment options are limited. Early detection significantly improves... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.